A patient at the HonorHealth Research Institute has become the first in Arizona to receive an investigational treatment for ischemic stroke that targets platelets instead of traditional clotting proteins. The drug, BB-031, is the first new medication for stroke in nearly three decades.
Stroke remains a significant health issue in the United States, ranking as the fourth leading cause of death and the main cause of long-term disability among adults. More than 160,000 Americans die from stroke each year.
HonorHealth Research Institute is participating in a national clinical trial called RAISE (Recanalization in Acute Ischemic Stroke), focusing on ischemic strokes. The institute is one of only a few sites nationwide offering this therapy and is currently the only site in Arizona.
The first patient at HonorHealth received BB-031 after being found ineligible for current standard therapies. Dr. Jadhav explained, "Many patients arrive too late or have medical conditions that prevent them from receiving the existing treatments. That's why expanding options is so critical."
BB-031 was developed by Basking Biosciences Inc. It works by inhibiting von Willebrand Factor (vWF), which plays a role in platelet adhesion during blood clot formation. By targeting this pathway, researchers hope to extend the treatment window and increase access for more patients who cannot use existing therapies.
Aptamers like BB-031 are small molecules made from nucleic acids that can be produced without animal-based manufacturing and offer greater stability compared to antibodies. This platform also allows for a rapid reversal agent if excess bleeding occurs.
"This opens the door for patients who may not have any other options," said Dr. Jadhav. "The potential advantages are tremendous."
Patients with suspected stroke across HonorHealth’s network are taken to Bob Bové Neuroscience Institute at HonorHealth Scottsdale Osborn Medical Center for advanced care and research participation.
